After misiu’s post I looked it up, yes, that is exactly it. He sold for a loss, and looks like he has been waiting to buy back. He will apparently focus on everything negative until he buys back. But the fact he spends so much time still keeping up with Cydy, sometimes first to post news, shows he has a serious interest in buying back in, his negativity can’t hide that. He should just admit he is timing his reentry, it would give him more credibility in my opinion. Yes, right now, he is better off if he sold, but there will come a time, very shortly in my opinion, he can’t say that unless he hurries, because after the secure this next funding to get past the BLA or end of year, NP gave numbers yesterday, the next after that is probably non-dilutive.

A17

2016
https://investorshub.advfn.com/boards/read_ms...=123746707

After ASM I sold 1/3 of my holdings at small profit to reduce my exposure and invest in another newly found biotech - that seems multibagger with 3-4 catalyst in H2-2016.

I think the good news/catalyst are not near so I am ready to sacrifice some profit - once the good news comes out I will buy again.
In my view r/s and uplisting will be next big catalyst. Start of monotherapy may not move the SP that much.

2017
https://investorshub.advfn.com/boards/read_ms...=135314906
In fact I already booked losses and sold my holding to reduce my exposure (it was at much higher price)

Commenting on buying opportunities after price drops post r/s, which he suspected then, end of 2016.
https://investorshub.advfn.com/boards/replies...=123746774
I am suspecting that - Dr will announce r/s before Aug to use the approval. If there is no good news to support the rls - the post split SP will drop and we may get sub $1 buying opportunity so I think we will get sub $ 1.40 buying opportunity.